Kristian Wachtell Selected Research

Hypertension (High Blood Pressure)

06/2008	Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
04/2008	Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
02/2007	Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
08/2006	N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
05/2006	Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
03/2006	Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
11/2005	Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
05/2005	Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy.
04/2005	Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
04/2005	Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.
03/2005	Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
03/2005	Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
02/2005	Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
01/2005	Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
01/2005	Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy.
09/2004	Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
09/2004	Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
09/2004	Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
08/2004	N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.
03/2004	N-terminal pro brain natriuretic peptide in arterial hypertension--a marker for left ventricular dimensions and prognosis.
12/2002	Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
09/2002	Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
09/2002	Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension.
07/2002	Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
05/2002	Vasodilatory capacity and vascular structure in long-standing hypertension: a LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension.
03/2002	Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
03/2002	Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
02/2002	Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension.

Articles by Research Topic

Disease

28	Hypertension (High Blood Pressure) 06/2008 - 02/2002
12	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 06/2008 - 02/2002
4	Atrial Fibrillation 08/2007 - 03/2005
4	Albuminuria 03/2006 - 09/2004
3	Aortic Valve Stenosis (Aortic Stenosis) 09/2008 - 04/2007
2	Sclerosis 11/2005 - 10/2004
2	Stroke (Strokes) 03/2005 - 01/2005
2	Hypertrophy 01/2005 - 07/2002
1	Bundle-Branch Block (Fascicular Block) 06/2008
1	Ventricular Tachycardia 02/2007
1	Myocardial Infarction 02/2007
1	Carotid Stenosis (Carotid Artery Stenosis) 03/2006
1	Syndrome 10/2005
1	Cardiomegaly (Heart Hypertrophy) 01/2005
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 08/2003
1	Heart Failure 02/2002

Drug/Important Bio-Agent (IBA)

29	Losartan (Cozaar)FDA Link 06/2008 - 02/2002
11	Atenolol (Tenormin)FDA LinkGeneric 03/2006 - 02/2002
4	Brain Natriuretic Peptide (Natrecor)FDA Link 08/2006 - 03/2004
3	ezetimibe (Zetia)FDA Link 09/2008 - 04/2007
3	Simvastatin (Zocor)FDA LinkGeneric 09/2008 - 04/2007
2	AngiotensinsIBA 08/2007 - 09/2006
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 09/2006
1	C-Reactive ProteinIBA 08/2006
1	Hemoglobins (Hemoglobin)IBA 05/2006
1	Natriuretic PeptidesIBA 05/2005
1	Insulin (Novolin)FDA Link 04/2005
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 03/2005
1	CreatinineIBA 02/2002
1	metoprolol succinate (Toprol-XL)FDA LinkGeneric 02/2002

Therapy/Procedure

1	Angioplasty (Angioplasties) 02/2007